CIK 0001682639 · Non-accelerated filer<br>Smaller reporting company
HYPERION DEFI, INC.
Sign in to watch- Ticker
- HYPD
- Exchange
- Nasdaq
- Industry
- Finance Services
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 471178401
- Phone
- 833-393-6684
- Business address
- 3090 NOWITZKI WAY, SUITE 300, DALLAS, TX, 75219
- Former names
- EYENOVIA, INC.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 5 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-08-18 | Grant Stuart M. 10% owner | Purchase | +724 | $3.93 | $3K | 4,339,583 |
| 2021-08-18 | Grant Stuart M. 10% owner | Purchase | +100 | $3.95 | $395 | 4,339,683 |
| 2021-08-18 | Grant Stuart M. 10% owner | Purchase | +100 | $3.95 | $395 | 4,339,783 |
| 2021-08-17 | Grant Stuart M. 10% owner | Purchase | +23,419 | $4.00 | $94K | 4,338,859 |
| 2021-06-17 | Clasby Jennifer G VP, Regulatory and Clinical | Option exercise | +24,510 | $1.95 | $48K | 80,212 |
| 2021-06-17 | Clasby Jennifer G VP, Regulatory and Clinical | Shares withheld for taxes | −13,675 | $5.42 | $74K | 66,537 |
| 2021-06-17 | Clasby Jennifer G VP, Regulatory and Clinical | Option exercise · Employee Stock Option (right to buy) | −24,510 | 0 | ||
| 2021-06-17 | Clasby Jennifer G VP, Regulatory and Clinical | Option exercise | +24,510 | $1.95 | $48K | 80,212 |
| 2021-06-17 | Clasby Jennifer G VP, Regulatory and Clinical | Shares withheld for taxes | −14,262 | $5.42 | $77K | 65,950 |
| 2021-06-17 | Clasby Jennifer G VP, Regulatory and Clinical | Option exercise · Employee Stock Option (right to buy) | −24,510 | 0 | ||
| 2021-06-16 | Ianchulev Tsontcho Chief Executive Officer | Grant or award · Stock Option (right to buy) | +139,867 | $6.01 | $841K | 139,867 |
| 2021-06-16 | GANDOLFO JOHN P Chief Financial Officer | Grant or award · Stock Option (right to buy) | +128,258 | $6.01 | $771K | 128,258 |
| 2021-06-16 | Rowe Michael M Chief Operating Officer | Grant or award · Stock Options (right to buy) | +128,258 | $6.01 | $771K | 128,258 |
| 2021-06-16 | Clasby Jennifer G VP, Regulatory and Clinical | Grant or award · Stock Option (right to buy) | +128,258 | $6.01 | $771K | 128,258 |
| 2021-06-16 | Clauson Luke VP Research & Development | Grant or award · Stock Option (right to buy) | +128,258 | $6.01 | $771K | 128,258 |
| 2021-06-15 | LEE KENNETH B JR Director | Purchase | +2,000 | $5.41 | $11K | 25,359 |
| 2021-06-14 | LEE KENNETH B JR Director | Purchase | +2,000 | $5.47 | $11K | 23,359 |
| 2021-06-11 | LEE KENNETH B JR Director | Purchase | +2,000 | $5.38 | $11K | 21,359 |
| 2021-05-28 | MATHER CHARLES E IV Director | Purchase | +3,000 | $4.76 | $14K | 26,359 |
| 2021-05-27 | Rowe Michael M Chief Operating Officer | Purchase | +1,400 | $4.71 | $7K | 2,800 |
Page 10 of 16 · 317 trades